TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Infant Study of Inhaled Saline in Cystic Fibrosis
Brief Summary: The purpose of this study is to assess whether 7% hypertonic saline (HS) is an effective and safe therapy in infants and young children with CF.


Options:
A: Arm Label: HS/sham; Type: EXPERIMENTAL; Interventions: Drug: inhaled hypertonic saline (7%) | Arm Label: sham/HS; Type: EXPERIMENTAL; Interventions: Drug: inhaled hypertonic saline (7%) | Intervention Type: DRUG; Name: inhaled hypertonic saline (7%); Assigned to Arm(s): HS/sham, sham/HS
B: Arm Label: USUAL CARE; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: INHALATION WITH PEP DEVICE; Type: ACTIVE_COMPARATOR; Interventions: Device: INHALATION WITH PEP DEVICE (Acapella Duet) | Intervention Type: DEVICE; Name: INHALATION WITH PEP DEVICE (Acapella Duet); Assigned to Arm(s): INHALATION WITH PEP DEVICE
C: Arm Label: group A; Type: EXPERIMENTAL; Interventions: Other: Inhalable Hypertonic saline 7% + Hyaluronan 0.1% | Arm Label: group B; Type: EXPERIMENTAL; Interventions: Other: Inhalable Hypertonic saline 7% | Intervention Type: OTHER; Name: Inhalable Hypertonic saline 7% + Hyaluronan 0.1%; Assigned to Arm(s): group A | Intervention Type: OTHER; Name: Inhalable Hypertonic saline 7%; Assigned to Arm(s): group B
D: Arm Label: Active treatment group; Type: EXPERIMENTAL; Interventions: Drug: 7% Hypertonic Saline (HS) | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9% Isotonic Saline (IS) | Intervention Type: DRUG; Name: 7% Hypertonic Saline (HS); Assigned to Arm(s): Active treatment group | Intervention Type: DRUG; Name: 0.9% Isotonic Saline (IS); Assigned to Arm(s): Control group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Infant Study of Inhaled Saline in Cystic Fibrosis
Brief Summary: The purpose of this study is to assess whether 7% hypertonic saline (HS) is an effective and safe therapy in infants and young children with CF.


Options:
A: Arm Label: 7% saline; Type: EXPERIMENTAL; Interventions: Drug: 7% saline | Arm Label: 0.12% saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.12% saline | Intervention Type: DRUG; Name: 0.12% saline; Assigned to Arm(s): 0.12% saline | Intervention Type: DRUG; Name: 7% saline; Assigned to Arm(s): 7% saline
B: Arm Label: Active treatment group; Type: EXPERIMENTAL; Interventions: Drug: 7% Hypertonic Saline (HS) | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9% Isotonic Saline (IS) | Intervention Type: DRUG; Name: 7% Hypertonic Saline (HS); Assigned to Arm(s): Active treatment group | Intervention Type: DRUG; Name: 0.9% Isotonic Saline (IS); Assigned to Arm(s): Control group
C: Arm Label: sodium chloride 6%; Type: EXPERIMENTAL; Interventions: Drug: sodium chloride 6% | Arm Label: sodium chloride 0,9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride 0,9% | Intervention Type: DRUG; Name: sodium chloride 6%; Assigned to Arm(s): sodium chloride 6% | Intervention Type: DRUG; Name: sodium chloride 0,9%; Assigned to Arm(s): sodium chloride 0,9%
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Health Economic Evaluation of Rapid Detection of Bacteraemia and Fungemia by Real Time PCR for Cases of Febrile Neutropenia, Suspicion of Endocarditis and Severe Sepsis in Intensive Care Units
Brief Summary: The primary purpose is to improve and quicken the microbial diagnosis in severe infections, since only one third of the cases are documented by blood cultures and adequate anti-infective therapy in the 48 hours reduced mortality and morbidity.

Our hypothesis is that detection of microbial DNA in blood by real time PCR may increase the number of cases diagnosed for bacteraemia or fungemia and shorten the time to positive results, which will provide information for an adequate anti-infectious therapy.


Options:
A: Arm Label: Standard blood culture and AST; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard Culture and AST | Arm Label: Rapid organism identification and AST; Type: ACTIVE_COMPARATOR; Interventions: Device: Accelerate PhenoTest™ BC Kit | Intervention Type: DEVICE; Name: Accelerate PhenoTest™ BC Kit; Assigned to Arm(s): Rapid organism identification and AST | Intervention Type: DEVICE; Name: Standard Culture and AST; Assigned to Arm(s): Standard blood culture and AST
B: Arm Label: Xpert MRSA/SA SSTI; Type: EXPERIMENTAL; Interventions: Device: Xpert MRSA/SA SSTI | Arm Label: Standard culture; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Standard culture | Intervention Type: DEVICE; Name: Xpert MRSA/SA SSTI; Assigned to Arm(s): Xpert MRSA/SA SSTI | Intervention Type: DIAGNOSTIC_TEST; Name: Standard culture; Assigned to Arm(s): Standard culture
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: detection of microbial DNA in blood by blood culture | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Detection of microbial DNA in blood by SeptiFast® | Intervention Type: OTHER; Name: Detection of microbial DNA in blood by SeptiFast®; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: detection of microbial DNA in blood by blood culture; Assigned to Arm(s): 2
D: Arm Label: Control; Type: EXPERIMENTAL; Interventions: Other: Bacterial culture, Other: Susceptibility testing | Arm Label: FilmArray test; Type: EXPERIMENTAL; Interventions: Device: FilmArray testing, Other: Bacterial culture, Other: Susceptibility testing | Arm Label: FilmArray plus antimicrobial stewardship; Type: EXPERIMENTAL; Interventions: Device: FilmArray testing, Behavioral: Antimicrobial Stewardship, Other: Bacterial culture, Other: Susceptibility testing | Intervention Type: DEVICE; Name: FilmArray testing; Assigned to Arm(s): FilmArray plus antimicrobial stewardship, FilmArray test | Intervention Type: BEHAVIORAL; Name: Antimicrobial Stewardship; Assigned to Arm(s): FilmArray plus antimicrobial stewardship | Intervention Type: OTHER; Name: Bacterial culture; Assigned to Arm(s): Control, FilmArray plus antimicrobial stewardship, FilmArray test | Intervention Type: OTHER; Name: Susceptibility testing; Assigned to Arm(s): Control, FilmArray plus antimicrobial stewardship, FilmArray test

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mass Oral Cholera Vaccination in High-risk Populations in Zanzibar: Assessment of Effectiveness and Herd Protection
Brief Summary: The purpose of this study is to conduct cholera vaccinations in high-risk populations in Zanzibar in order to estimate herd protection conferred by the vaccine,estimate effectiveness of the vaccine, and describe the interaction of vaccination and improved water supply on the burden of cholera and diarrhoeal diseases.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: bivalent killed whole cell oral cholera vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: bivalent killed whole cell oral cholera vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: cholvax; Type: EXPERIMENTAL; Interventions: Biological: Cholvax | Arm Label: shanchol; Type: ACTIVE_COMPARATOR; Interventions: Biological: Shanchol | Intervention Type: BIOLOGICAL; Name: Cholvax; Assigned to Arm(s): cholvax | Intervention Type: BIOLOGICAL; Name: Shanchol; Assigned to Arm(s): shanchol
C: Arm Label: Shanchol; Type: EXPERIMENTAL; Interventions: Biological: Shanchol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Shanchol; Assigned to Arm(s): Shanchol | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: rBS-WC vaccine | Intervention Type: BIOLOGICAL; Name: rBS-WC vaccine; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Disseminating Effective Habits for Long-Term Weight Loss
Brief Summary: The purpose of the study is to determine whether using a web-based weight loss website can help overweight individuals lose weight.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Disseminating Effective Habits for Long-term Weight Loss, Behavioral: Achieve Together website | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Disseminating Effective Habits for Long-term Weight Loss; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Achieve Together website; Assigned to Arm(s): 1
B: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: lifestyle counseling | Arm Label: Cognitive Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Training | Intervention Type: BEHAVIORAL; Name: lifestyle counseling; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Cognitive Training; Assigned to Arm(s): Cognitive Training
C: Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Behavioral Weight Loss Program | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Stepped-Care Weight Loss Program | Intervention Type: BEHAVIORAL; Name: Standard Behavioral Weight Loss Program; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Stepped-Care Weight Loss Program; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Tobacco as a Harm Reduction Product: Study 2 - Efficacy of Oral Tobacco Products Compared to Medicinal Nicotine for Complete Cigarette Substitution and Among Non-abstainers, for Reduction in Cigarette Smoking
Brief Summary: For the primary goals, we hypothesize that 1) the oral tobacco product will be more efficacious than the medicinal nicotine product in substituting for smoking cigarettes; 2) among non-abstainers, the oral tobacco product will lead to greater reduction in cigarette smoking than medicinal nicotine; and 3) a higher rate of oral tobacco compared to medicinal nicotine use will be observed during and beyond the treatment period.

For the secondary goals, we hypothesize that 1) both products will equally reduce withdrawal symptoms from cigarette abstinence; and 2) the toxicant exposure and toxicity will be reduced dramatically when smokers switch from cigarettes to each of these products; however, this reduction will be greater with the use of medicinal nicotine.


Options:
A: Arm Label: Nicotine Gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Gum | Arm Label: Snus; Type: EXPERIMENTAL; Interventions: Other: Oral tobacco | Intervention Type: OTHER; Name: Oral tobacco; Assigned to Arm(s): Snus | Intervention Type: DRUG; Name: Nicotine Gum; Assigned to Arm(s): Nicotine Gum
B: Arm Label: CO reminder; Type: EXPERIMENTAL; Interventions: Behavioral: Informing surgical patients about CO monitoring | Arm Label: no CO reminder; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: a brief intervention recommending preoperative abstinence from smoking | Intervention Type: BEHAVIORAL; Name: Informing surgical patients about CO monitoring; Assigned to Arm(s): CO reminder | Intervention Type: BEHAVIORAL; Name: a brief intervention recommending preoperative abstinence from smoking; Assigned to Arm(s): no CO reminder
C: Arm Label: HIGH NICOTINE; Type: N/A; Interventions: N/A
D: Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: NIMH Collaborative HIV/STD Prevention Trial
Brief Summary: This study will evaluate the effectiveness of a community-level HIV prevention program in promoting safer sexual behaviors and reducing the transmission of HIV/sexually transmitted diseases among at-risk populations in China, India, Peru, Russia, and Zimbabwe.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Community Popular Opinion Leader (C-POL), Behavioral: HIV/STD educational materials | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: HIV/STD educational materials | Intervention Type: BEHAVIORAL; Name: Community Popular Opinion Leader (C-POL); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: HIV/STD educational materials; Assigned to Arm(s): 1, 2
B: Intervention Type: BEHAVIORAL; Name: In-school Sexual Health Education; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Youth-friendly health services; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Youth condom promotion & distribution; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Community activities related to adolescent sexual health; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: HORIZONS HIV Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: enhanced standard-of-care | Intervention Type: BEHAVIORAL; Name: HORIZONS HIV Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: enhanced standard-of-care; Assigned to Arm(s): 2
D: Intervention Type: DEVICE; Name: Ortho All-Flex diaphragm and Replens lubricant gel; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Observer and Subject Masked Trial Comparing the Visual Outcome After Treatment With Ranibizumab or Bevacizumab in Patients With Neovascular Age-related Macular Degeneration Multicenter Anti VEGF Trial in Austria (MANTA)
Brief Summary: Angiogenesis plays a key role in the development of choroidal neovascularizations (CNV) in age-related macular degeneration. Vascular endothelial growth factor (VEGF) is the most important factor involved in this angiogenetic processes in the eye. This forms the basis for new therapeutic interventions in exudative AMD. Currently two drugs have been approved by the FDA and one drug is used off-label. All these drugs are administered intravitreally. The present study aims to directly compare the effects ranibizumab and bevacizumab in a randomized controlled study in patients with neovascular AMD.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): B
B: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
C: Arm Label: Aflibercept Blood Sample Collection; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood Sample Collection, Drug: Aflibercept | Arm Label: Bevacizumab Blood Sample Collection; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood Sample Collection, Drug: Bevacizumab | Arm Label: Ranibizumab Blood Sample Collection; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood Sample Collection, Drug: Ranibizumab | Intervention Type: BIOLOGICAL; Name: Blood Sample Collection; Assigned to Arm(s): Aflibercept Blood Sample Collection, Bevacizumab Blood Sample Collection, Ranibizumab Blood Sample Collection | Intervention Type: DRUG; Name: Aflibercept; Assigned to Arm(s): Aflibercept Blood Sample Collection | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab Blood Sample Collection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab Blood Sample Collection
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Observer and Subject Masked Trial Comparing the Visual Outcome After Treatment With Ranibizumab or Bevacizumab in Patients With Neovascular Age-related Macular Degeneration Multicenter Anti VEGF Trial in Austria (MANTA)
Brief Summary: Angiogenesis plays a key role in the development of choroidal neovascularizations (CNV) in age-related macular degeneration. Vascular endothelial growth factor (VEGF) is the most important factor involved in this angiogenetic processes in the eye. This forms the basis for new therapeutic interventions in exudative AMD. Currently two drugs have been approved by the FDA and one drug is used off-label. All these drugs are administered intravitreally. The present study aims to directly compare the effects ranibizumab and bevacizumab in a randomized controlled study in patients with neovascular AMD.


Options:
A: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): B
C: Arm Label: Bevacizumab 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab 1 | Arm Label: Bevacizumab 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab 1; Assigned to Arm(s): Bevacizumab 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab 2
D: Arm Label: bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): bevacizumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Non-invasive Ventilation in Patients With Severe Chronic Obstructive Pulmonary Disease and Lung Emphysema (COPD)
Brief Summary: Non-invasive ventilation is frequently applied in patients with acute exacerbation of COPD, but no evidence exists about the effect of long term application/home application.

This study tests the hypothesis, that a daily, 6 hour application of non-invasive ventilation over one year improves survival, exercise capacity, and quality of life in patients with advanced stages of COPD.


Options:
A: Arm Label: NPPV group; Type: EXPERIMENTAL; Interventions: Device: ventilators designed for non invasive ventilation | Arm Label: control gorup; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: ventilators designed for non invasive ventilation; Assigned to Arm(s): NPPV group
B: Arm Label: Long term oxygen therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Long term oxygen therapy | Arm Label: Home mechanical ventilation; Type: EXPERIMENTAL; Interventions: Device: Home mechanical ventilation | Intervention Type: DEVICE; Name: Home mechanical ventilation; Assigned to Arm(s): Home mechanical ventilation | Intervention Type: DEVICE; Name: Long term oxygen therapy; Assigned to Arm(s): Long term oxygen therapy
C: Arm Label: Active Treatment; Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous Positive Airway Pressure (CPAP) Treatment | Arm Label: Sham/Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Device: Sham CPAP device - CPAP device with pressure delivered <1 cm H20 | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP) Treatment; Assigned to Arm(s): Active Treatment | Intervention Type: DEVICE; Name: Sham CPAP device - CPAP device with pressure delivered <1 cm H20; Assigned to Arm(s): Sham/Placebo Treatment
D: Arm Label: Noninvasive ventilator; Type: EXPERIMENTAL; Interventions: Device: BiPAP mode | Arm Label: LTOT; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: BiPAP mode; Assigned to Arm(s): Noninvasive ventilator

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Non-invasive Ventilation in Patients With Severe Chronic Obstructive Pulmonary Disease and Lung Emphysema (COPD)
Brief Summary: Non-invasive ventilation is frequently applied in patients with acute exacerbation of COPD, but no evidence exists about the effect of long term application/home application.

This study tests the hypothesis, that a daily, 6 hour application of non-invasive ventilation over one year improves survival, exercise capacity, and quality of life in patients with advanced stages of COPD.


Options:
A: Arm Label: Smokers without COPD; Type: N/A; Interventions: N/A | Arm Label: Severe COPD; Type: N/A; Interventions: N/A | Arm Label: Mild/Moderate COPD; Type: N/A; Interventions: N/A | Arm Label: Non-smokers; Type: N/A; Interventions: N/A
B: Arm Label: NHW COPD Participants; Type: N/A; Interventions: N/A | Arm Label: NHW Control Group; Type: N/A; Interventions: N/A | Arm Label: AA COPD Participants; Type: N/A; Interventions: N/A | Arm Label: AA Control Group; Type: N/A; Interventions: N/A
C: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
D: Arm Label: NPPV group; Type: EXPERIMENTAL; Interventions: Device: ventilators designed for non invasive ventilation | Arm Label: control gorup; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: ventilators designed for non invasive ventilation; Assigned to Arm(s): NPPV group

Answer: D